Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
Participant recruitment and retention can be challenged by many factors such as a long follow-up period, lack of accessible sites and unclear expectations. Our team helps develop and implement agile solutions to overcome these difficulties, as described in this video for multiple studies including a global, multi-site oncology trial.
Investigating existing treatments for their efficacy to treat COVID-19 is important in some countries with limited access to new treatments, such as Ghana. In this project profile, Loice Magaria, Clinical Research Project Manager at FHI Clinical, discusses a study we’re supporting in Ghana to investigate COVID-19 treatments.
With infectious disease outbreaks, expanding immunity from previous infection and vaccination efforts can change where the outbreak is occurring. In this video, Loice Magaria, Clinical Research Project Manager at FHI Clinical discusses strategies implemented to address changing epidemiology in a study investigating COVID-19 treatments.
In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
Discovered in the 1960s, coronaviruses (CoV) are a large group of RNA viruses in the family Coronaviridae that cause disease in humans and animal species. Human illness includes respiratory infections that range from the common cold to viral (direct) or bacterial (indirect) pneumonia and are especially serious in infants and at-risk adults. There are seven known coronavirus types/strains.
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”
In this webinar, industry veterans Michelle Berrey, MD, MPH, and Claudia Christian discuss the importance of quality data for a successful outbreak response plan.